Compare DFH & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DFH | VIR |
|---|---|---|
| Founded | 2008 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.5B |
| IPO Year | 2020 | 2019 |
| Metric | DFH | VIR |
|---|---|---|
| Price | $14.08 | $9.06 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $26.00 | $19.63 |
| AVG Volume (30 Days) | 675.2K | ★ 2.3M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 17.49 |
| EPS | ★ 2.14 | N/A |
| Revenue | ★ $4,322,848,000.00 | $68,556,000.00 |
| Revenue This Year | $0.81 | N/A |
| Revenue Next Year | $7.82 | $1,049.62 |
| P/E Ratio | $6.56 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.41 | $4.16 |
| 52 Week High | $31.10 | $10.91 |
| Indicator | DFH | VIR |
|---|---|---|
| Relative Strength Index (RSI) | 36.47 | 52.52 |
| Support Level | N/A | $8.67 |
| Resistance Level | $14.75 | $10.29 |
| Average True Range (ATR) | 0.69 | 0.46 |
| MACD | 0.10 | -0.09 |
| Stochastic Oscillator | 27.45 | 48.74 |
Dream Finders Homes Inc designs, builds and sells homes in markets throughout the United States. The company's primary focus is on constructing and selling single-family homes across entry-level, first-time move-up, second-time move-up, and active adult markets. Its homebuilding operations are organized into four reportable segments: Southeast, Mid-Atlantic, Midwest, and Financial Services. It generates the maximum of its revenue from the Midwest segment.
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.